Sex differences in the escalation of oral phencyclidine (PCP) self-administration under FR and PR schedules in rhesus monkeys.
BACKGROUND
Studies with male rats indicate that long access (LgA) vs short access (ShA) to i.v. cocaine and heroin self-administration leads to an escalation of drug intake and a subsequent upward shift of the dose-response function.


OBJECTIVE
The purpose of this experiment was to extend these results to male and female rhesus monkeys and oral phencyclidine (PCP) self-administration under fixed-ratio (FR) and progressive-ratio (PR) schedules.


METHODS
Adult rhesus monkeys (seven females and nine males) orally self-administered PCP (0.25 mg/ml) and water under concurrent FR 16 FR 16 schedules during daily ShA 3-h sessions. Since females weighed less than males, each liquid delivery (0.6 ml) represented a higher unit dose mg/kg for females than males, but drug concentration mg/ml remained constant. Concurrent PR PR schedules were then used to obtain a concentration-response function (0.125, 0.25, 0.5, and 1.0 mg/ml). Next, PCP and water were available during LgA 6-h sessions under concurrent FR 16 FR 16 schedules for 21 days. The monkeys were then retested under the concurrent FR 16 FR 16 and PR PR conditions during ShA sessions.


RESULTS
Under the initial ShA concurrent FR 16 FR 16 schedules, females and males did not differ on PCP deliveries or intake (mg/kg); however, during LgA, males and females had more PCP deliveries compared with ShA. During LgA, males exceeded females in PCP deliveries, but females were higher than males in mg/kg PCP intake. Also, PCP (but not water) deliveries and mg/kg PCP intake significantly increased from the first 3 days to the last 3 days of the 21-day LgA period in both males and females. The subsequent ShA FR 16 FR 16 performance did not differ by sex, but it was significantly elevated above the first ShA period in both sexes. The concentration-response function for PCP break point under the PR PR schedules and PCP intake (mg/kg) were significantly shifted upward during the second (vs first) ShA period, and females' mg/kg intake significantly exceeded males'.


CONCLUSIONS
Male and female rhesus monkeys both showed escalation of PCP self-administration during LgA to PCP and during ShA that occurred after (vs before) LgA. Both showed vertical upward shifts in the concentration x intake (mg/kg) function under the PR schedule, and females exceeded males on this measure. These findings with PCP and monkeys are consistent with vertical upward shifts of cocaine dose-response functions in previous escalation studies in male rats and reports of sex differences (F>M) during several other phases of drug abuse.
Carroll
Marilyn E
ME
Department of Psychiatry, University of Minnesota, MMC 392, Minneapolis, MN 55455, USA. mcarroll@umn.edu
Batulis
David K
DK
Landry
Kerry L
KL
Morgan
Andrew D
AD
D000284:Administration, Oral; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004326:Drinking; D005260:Female; D006213:Hallucinogens / Q000008:administration & dosage; D008253:Macaca mulatta; D008297:Male; D010622:Phencyclidine / Q000008:administration & dosage*; D012055:Reinforcement Schedule; D012646:Self Administration; D012737:Sex Factors; D013997:Time Factors; D014867:Water / Q000008:administration & dosage
D006213:Hallucinogens; D014867:Water; D010622:Phencyclidine
Br J Psychiatry. 1985 Nov;147:569-73
4075057
Psychopharmacology (Berl). 2003 Oct;170(1):9-16
12838382
J Neural Transm (Vienna). 2000;107(6):649-68
10943906
Drug Alcohol Depend. 2004 Jun 11;74(3):265-72
15194204
Psychopharmacology (Berl). 2000 Feb;148(3):289-98
10755742
Science. 1991 Mar 29;251(5001):1580-6
2011738
Pharmacol Biochem Behav. 1984 May;20(5):779-87
6739518
Psychopharmacology (Berl). 1989;98(3):408-11
2501818
Psychopharmacology (Berl). 2000 Sep;151(4):392-405
11026746
Synapse. 1991 Oct;9(2):121-8
1821483
Brain Res. 1999 Aug 21;839(1):85-93
10482802
Brain Res. 1994 Feb 21;637(1-2):163-72
8180794
Psychopharmacology (Berl). 2004 Apr;173(1-2):64-72
14712336
Exp Clin Psychopharmacol. 2004 May;12(2):111-7
15122955
Psychopharmacology (Berl). 1995 Jul;120(1):10-20
7480530
Psychopharmacology (Berl). 2001 Aug;157(1):31-9
11512040
Psychopharmacology (Berl). 1999 May;144(2):163-74
10394998
Pharmacol Biochem Behav. 1999 Dec;64(4):803-12
10593204
Neuron. 1998 Sep;21(3):467-76
9768834
Neuroendocrinology. 1981 Mar;32(3):168-73
7219671
Neuropsychopharmacology. 2001 Feb;24(2):97-129
11120394
Behav Pharmacol. 2002 Sep;13(5-6):389-96
12394415
Psychopharmacology (Berl). 2002 Oct;164(1):19-26
12373415
Trends Pharmacol Sci. 2004 May;25(5):273-9
15120494
Psychopharmacology (Berl). 2005 Feb;178(1):41-51
15338102
Exp Neurol. 1994 Feb;125(2):306-11
8313946
Neuropsychopharmacology. 2000 Apr;22(4):413-21
10700660
Psychopharmacology (Berl). 2004 Jan;171(3):349-51; author reply 352-63
14530895
Brain Res. 1993 Apr 30;610(1):127-34
8518920
Neuroscience. 2000;95(4):1061-70
10682713
Drug Alcohol Depend. 1982 Jul;9(3):213-24
7117133
Psychopharmacology (Berl). 2003 Jul;168(1-2):192-200
12402103
J Neurochem. 2003 Jul;86(1):102-13
12807430
Psychopharmacology (Berl). 2000 Feb;148(2):196-200
10663435
Psychopharmacology (Berl). 1999 Feb;141(4):436-46
10090652
Psychopharmacologia. 1974 Jan 14;34(3):255-64
4819978
Exp Clin Psychopharmacol. 2001 May;9(2):131-43
11518086
Neurosci Biobehav Rev. 2004 Jan;27(8):739-49
15019424
Psychopharmacology (Berl). 2004 Apr;172(4):450-4
14647962
Psychopharmacology (Berl). 2000 Oct;152(2):132-9
11057516
Psychopharmacology (Berl). 1999 Oct;146(3):303-12
10541731
Eur J Pharmacol. 1984 Jan 27;97(3-4):217-27
6538506
Addiction. 1999 Sep;94(9):1413-9
10615725
Exp Clin Psychopharmacol. 2006 Feb;14(1):68-78
16503706
Psychopharmacologia. 1976 Apr 15;46(3):229-33
951458
Pharmacol Biochem Behav. 2004 Jun;78(2):199-207
15219759
Science. 1997 Oct 3;278(5335):52-8
9311926
Behav Brain Res. 1995 Sep;70(1):77-94
8519431
Brain Res. 1990 Apr 23;514(1):22-6
2357527
Psychopharmacology (Berl). 1980;70(1):5-10
6775335
Psychopharmacology (Berl). 2000 May;149(4):401-8
10867968
Ann N Y Acad Sci. 1973 Apr 30;215:162-5
4196889
Psychopharmacology (Berl). 1998 Dec;140(4):510-8
9888628
Neuropsychopharmacology. 2004 Apr;29(4):669-75
14694351
Psychopharmacology (Berl). 2002 Nov;164(2):121-37
12404074
Health Psychol. 1991;10(2):121-32
2055210
J Neurosci. 2003 Jan 15;23(2):693-9
12533629
NIDA Res Monogr. 1998 Mar;169:105-33
9686413
Science. 1989 Sep 29;245(4925):1511-3
2781295
Nat Neurosci. 2002 Jul;5(7):625-6
12055635
Drug Alcohol Depend. 1993 Sep;33(2):119-28
8261876
Science. 1977 Oct 7;198(4312):67-9
408925
Psychopharmacology (Berl). 1999 May;144(1):77-82
10379627
Fed Proc. 1982 Feb;41(2):211-5
7199481
Psychopharmacology (Berl). 2004 Aug;175(1):26-36
15042275
Science. 1998 Oct 9;282(5387):298-300
9765157
Psychoneuroendocrinology. 2003 Oct;28(7):836-62
12892653
Pharmacol Biochem Behav. 1982 Aug;17(2):341-6
7134242
Psychopharmacologia. 1969;16(1):30-48
4982648
J Pharmacol Exp Ther. 1973 May;185(2):307-16
4634092
Psychiatr Clin North Am. 1999 Jun;22(2):241-52
10385931
Exp Clin Psychopharmacol. 1998 Feb;6(1):22-31
9526143
Drug Alcohol Depend. 2002 Sep 1;68(1):65-85
12167553
Brain Res. 2004 Jan 2;995(1):46-54
14644470